半胱氨酸154精氨酸取代在核糖体蛋白L3中对结核分枝杆菌恶唑烷酮耐药性的作用。
Role of the Cys154Arg Substitution in Ribosomal Protein L3 in Oxazolidinone Resistance in Mycobacterium tuberculosis.
作者信息
Makafe Gaëlle Guiewi, Cao Yuanyuan, Tan Yaoju, Julius Mugweru, Liu Zhiyong, Wang Changwei, Njire Moses M, Cai Xingshan, Liu Tianzhou, Wang Bangxing, Pang Wei, Tan Shouyong, Zhang Buchang, Yew Wing Wai, Lamichhane Gyanu, Guo Jintao, Zhang Tianyu
机构信息
State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), Guangzhou, China.
State Key Laboratory of Respiratory Disease, Guangzhou Institutes of Biomedicine and Health (GIBH), Chinese Academy of Sciences (CAS), Guangzhou, China School of Life Sciences, Anhui University, Hefei, China.
出版信息
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3202-6. doi: 10.1128/AAC.00152-16. Print 2016 May.
Abstract
We expressed the wild-type rplC and mutated rplC (Cys154Arg) genes, respectively, in Mycobacterium tuberculosis H37Ra and H37Rv in an attempt to delineate the role of rplC (Cys154Arg) regarding oxazolidinone resistance. An increase of the MICs of linezolid (LZD) and sutezolid (PNU-100480, PNU) against the recombinant mycobacteria with overexpressed rplC mutation (Cys154Arg) was found, suggesting the rplC gene is a determinant of bacillary susceptibilities to LZD and PNU.
摘要
我们分别在结核分枝杆菌H37Ra和H37Rv中表达了野生型rplC基因和突变型rplC（Cys154Arg）基因，试图阐明rplC（Cys154Arg）在恶唑烷酮耐药性方面的作用。结果发现，利奈唑胺（LZD）和舒他唑胺（PNU-100480，PNU）对过表达rplC突变体（Cys154Arg）的重组分枝杆菌的最低抑菌浓度（MIC）有所增加，这表明rplC基因是细菌对LZD和PNU敏感性的一个决定因素。
相似文献
1
Role of the Cys154Arg Substitution in Ribosomal Protein L3 in Oxazolidinone Resistance in Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2016 Apr 22;60(5):3202-6. doi: 10.1128/AAC.00152-16. Print 2016 May.
2
Isolation and Characterization of Oxazolidinone-Resistant Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2017 Sep 22;61(10). doi: 10.1128/AAC.01296-17. Print 2017 Oct.
3
rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains.
Antimicrob Agents Chemother. 2012 May;56(5):2743-5. doi: 10.1128/AAC.06227-11. Epub 2012 Feb 27.
4
Mycobacterium tuberculosis Mutations Associated with Reduced Susceptibility to Linezolid.
Antimicrob Agents Chemother. 2016 Mar 25;60(4):2542-4. doi: 10.1128/AAC.02941-15. Print 2016 Apr.
5
Different Resistance Mechanisms for Cadazolid and Linezolid in Clostridium difficile Found by Whole-Genome Sequencing Analysis.
Antimicrob Agents Chemother. 2017 Jul 25;61(8). doi: 10.1128/AAC.00384-17. Print 2017 Aug.
6
Examination of bedaquiline- and linezolid-resistant Mycobacterium tuberculosis isolates from the Moscow region.
J Antimicrob Chemother. 2017 Jul 1;72(7):1901-1906. doi: 10.1093/jac/dkx094.
7
In vitro activities of PNU-100480 and linezolid against drug-susceptible and drug-resistant Mycobacterium tuberculosis isolates.
Int J Antimicrob Agents. 2013 Jul;42(1):96-7. doi: 10.1016/j.ijantimicag.2013.03.002. Epub 2013 May 15.
8
Promising antituberculosis activity of the oxazolidinone PNU-100480 relative to that of linezolid in a murine model.
Antimicrob Agents Chemother. 2009 Apr;53(4):1314-9. doi: 10.1128/AAC.01182-08. Epub 2008 Dec 15.
9
Agreement between Phenotypically Detected Linezolid Resistance and Mutations in rrl and rplC Genes of Mycobacterium tuberculosis Isolates Using Nanopore Sequencing.
Int J Mycobacteriol. 2024 Jul 1;13(3):331-336. doi: 10.4103/ijmy.ijmy_139_24. Epub 2024 Sep 14.
10
First linezolid-resistant clinical isolates of Mycobacterium tuberculosis.
Antimicrob Agents Chemother. 2007 Apr;51(4):1534-6. doi: 10.1128/AAC.01113-06. Epub 2007 Jan 22.
引用本文的文献
1
Mutations in ClpC1 or ClpX subunit of caseinolytic protease confer resistance to ilamycins in mycobacteria.
Commun Biol. 2025 Aug 13;8(1):1219. doi: 10.1038/s42003-025-08646-z.
2
GrcC1 mediates low-level resistance to multiple drugs in , and .
Microbiol Spectr. 2025 Apr;13(4):e0228924. doi: 10.1128/spectrum.02289-24. Epub 2025 Feb 26.
3
Antitubercular drugs: possible role of natural products acting as antituberculosis medication in overcoming drug resistance and drug-induced hepatotoxicity.
Naunyn Schmiedebergs Arch Pharmacol. 2024 Mar;397(3):1251-1273. doi: 10.1007/s00210-023-02679-z. Epub 2023 Sep 4.
4
Characterization of Resistance to Linezolid in Mycobacterium abscessus.
Microbiol Spectr. 2023 Aug 17;11(4):e0219923. doi: 10.1128/spectrum.02199-23. Epub 2023 Jul 17.
5
Mechanisms of Linezolid Resistance in Mycobacteria.
Pharmaceuticals (Basel). 2023 May 24;16(6):784. doi: 10.3390/ph16060784.
6
Application of Next Generation Sequencing for Diagnosis and Clinical Management of Drug-Resistant Tuberculosis: Updates on Recent Developments in the Field.
Front Microbiol. 2022 Mar 24;13:775030. doi: 10.3389/fmicb.2022.775030. eCollection 2022.
7
Anti-tuberculosis drug resistance in Slovakia, 2018-2019: The first whole-genome epidemiological study.
J Clin Tuberc Other Mycobact Dis. 2021 Dec 20;26:100292. doi: 10.1016/j.jctube.2021.100292. eCollection 2022 Feb.
8
Profiling Pretomanid as a Therapeutic Option for TB Infection: Evidence to Date.
Drug Des Devel Ther. 2021 Jun 28;15:2815-2830. doi: 10.2147/DDDT.S281639. eCollection 2021.
9
Genetic and Virulence Characteristics of Linezolid and Pretomanid Dual Drug-Resistant Strains Induced from in vitro.
Infect Drug Resist. 2020 Jun 12;13:1751-1761. doi: 10.2147/IDR.S257145. eCollection 2020.
10
Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid.
J Antimicrob Chemother. 2020 Aug 1;75(8):2031-2043. doi: 10.1093/jac/dkaa136.
本文引用的文献
1
Role of folP1 and folP2 Genes in the Action of Sulfamethoxazole and Trimethoprim Against Mycobacteria.
J Microbiol Biotechnol. 2015 Sep;25(9):1559-67. doi: 10.4014/jmb.1503.03053.
2
Mutations in the bacterial ribosomal protein l3 and their association with antibiotic resistance.
Antimicrob Agents Chemother. 2015;59(6):3518-28. doi: 10.1128/AAC.00179-15. Epub 2015 Apr 6.
3
Engineering more stable, selectable marker-free autoluminescent mycobacteria by one step.
PLoS One. 2015 Mar 11;10(3):e0119341. doi: 10.1371/journal.pone.0119341. eCollection 2015.
4
Mycobactericidal activity of sutezolid (PNU-100480) in sputum (EBA) and blood (WBA) of patients with pulmonary tuberculosis.
PLoS One. 2014 Apr 14;9(4):e94462. doi: 10.1371/journal.pone.0094462. eCollection 2014.
5
Beijing genotype of Mycobacterium tuberculosis is significantly associated with linezolid resistance in multidrug-resistant and extensively drug-resistant tuberculosis in China.
Int J Antimicrob Agents. 2014 Mar;43(3):231-5. doi: 10.1016/j.ijantimicag.2013.12.007. Epub 2013 Dec 31.
6
Bactericidal activity and mechanism of action of AZD5847, a novel oxazolidinone for treatment of tuberculosis.
Antimicrob Agents Chemother. 2014;58(1):495-502. doi: 10.1128/AAC.01903-13. Epub 2013 Nov 4.
7
WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis.
Antimicrob Agents Chemother. 2013 Sep;57(9):4097-104. doi: 10.1128/AAC.00120-13. Epub 2013 Jun 17.
8
Susceptibility testing of extensively drug-resistant and pre-extensively drug-resistant Mycobacterium tuberculosis against levofloxacin, linezolid, and amoxicillin-clavulanate.
Antimicrob Agents Chemother. 2013 Jun;57(6):2522-5. doi: 10.1128/AAC.02020-12. Epub 2013 Mar 18.
9
Linezolid for treatment of chronic extensively drug-resistant tuberculosis.
N Engl J Med. 2012 Oct 18;367(16):1508-18. doi: 10.1056/NEJMoa1201964.
10
rplC T460C identified as a dominant mutation in linezolid-resistant Mycobacterium tuberculosis strains.
Antimicrob Agents Chemother. 2012 May;56(5):2743-5. doi: 10.1128/AAC.06227-11. Epub 2012 Feb 27.
Zotero 插件